# US 2015/0306130 A1 · Chitosan covalently linked with small molecule integrin antagonist for targeted delivery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0306130 A1
- Document ID: US20150306130A1
- Status: Published application
- Kind: A1
- Application number: 14/373,669
- Filed: 2013-01-24
- Published: 2015-10-29
- Earliest claimed: 2012-01-27
- Assignees: Hoffmann-La Roche Inc.
- Applicants: Hoffmann-La Roche Inc.
- Inventors: Jayne CHIN; Robert Alan Goodnow, JR.; Matthew Michael Hamilton; Achyutharao Sidduri
- Web page: https://patentgrep.com/patent/US20150306130A1

## CPC

- A61K 31/722: Chitin, chitosan
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 47/61: the organic macromolecular compound being a polysaccharide or a derivative thereof
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- C08B 37/003: {Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)

## Abstract

The invention relates to the chitosan polymer derivatives of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Y, X1, X4, R1, R2, and n are defined in the detailed description and claims. The chitosan polymer derivatives of formula I bind to or associate with alpha-4-beta-1 (α4β1) and alpha-V-beta-3 (αVβ3) integrin dimers and can be used in delivery formulations to deliver drugs, nucleic acids, or other therapeutic compounds to tissues or cells expressing such integrins.

## Claims

### Claim 1

A chitosan polymer derivative of formula I:
wherein the monomers of formula I are covalently linked to each other by a single oxygen atom at positions X1 and X4 which represent beta-1-4 linkages, except at the terminal ends of the polymer wherein X1 and X4 represent hydroxy of any stereochemistry; and wherein:
Y is selected from the group consisting of:
(1) a moiety of the formula:
and
(2) a moiety of the formula:
R1 is selected from the group consisting of:
(1) a moiety of the formula:
wherein m is 0 or 1; and
(2) a moiety of the formula:
wherein
is:
R2 is hydrogen or methyl, and n is 8-25.

### Claim 2 (depends on 1)

A chitosan polymer derivative according to claim 1 wherein Y is:

### Claim 3 (depends on 1)

A chitosan polymer derivative according to claim 1 wherein Y is:

### Claim 4 (depends on 1, 2, 3)

A chitosan polymer derivative according to any one of claims 1 to 3 wherein R1 is:

### Claim 5 (depends on 1, 2, 3)

A chitosan polymer derivative according to any one of claims 1 to 3 wherein R1 is:

### Claim 6 (depends on 5)

A chitosan polymer derivative according to claim 5 wherein:

### Claim 7 (depends on 5)

A chitosan polymer derivative according to claim 5 wherein:

### Claim 8 (depends on 5)

A chitosan polymer derivative according to claim 5 wherein:

### Claim 9 (depends on 5)

A chitosan polymer derivative according to claim 5 wherein:

### Claim 10 (depends on 1)

A chitosan polymer derivative according to claim 1 which is:
Cs(AK)-Pr-S-αvβ3 Ligand 2 (Chitosan Derivative A), 2.5% N-acetyl-chitosan loaded with 0.15% of (S)—N-[4-[3-[3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[3-(2,5- dioxo-2,5-dihydro-pyrrol-1-yl)-propionylamino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-1-oxopropyl]amino]propoxy]-phenyl]-3-[2-[3-[guanidino]-benzoylamino]-acetylamino]-succinamic acid.

### Claim 11 (depends on 1)

A chitosan polymer derivative according to claim 1 which is:
Cs(AK)-Pr-S-αvβ3 Ligand 2 (Chitosan Derivative B), 2.5% N-acetyl-chitosan loaded with 0.21% of (S)—N-[4-[3-[3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[3-(2,5- dioxo-2,5-dihydro-pyrrol-1-yl)-propionylamino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-1-oxopropyl]amino]propoxy]-phenyl]-3-[2-[3-[guanidino]-benzoylamino]-acetylamino]-succinamic acid.

### Claim 12 (depends on 1)

A chitosan polymer derivative according to claim 1 which is:
Cs(AK)-Pr-S-αvβ3 Ligand 2 (Chitosan Derivative C), 2.5% N-acetyl-chitosan loaded with 0.76% of (S)-[N-[4-[3-[3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[3-(2,5- dioxo-2,5-dihydro-pyrrol-1-yl)-propionylamino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-1-oxopropyl]amino]propoxy]-phenyl]-3-[2-[3-[guanidino]-benzoylamino]-acetylamino]-succinamic acid.

### Claim 13 (depends on 1)

A chitosan polymer derivative according to claim 1 which is:
Cs(NM)-Pr-S-αvβ3 Ligand 3 (Chitosan Derivative D), 14% N-acetyl-chitosan loaded with 0.3% of (S)—N-[4-[3-[3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[3-(2,5-dioxo- 2,5-dihydro-pyrrol-1-yl)-propionylamino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-1-oxopropyl]amino]ethoxy]-phenyl]-3-[2-[3-[guanidino]-benzoylamino]-acetylamino]-succinamic acid.

### Claim 14 (depends on 1)

A chitosan polymer derivative according to claim 1 which is:
Cs(NM)-Pr-S-αvβ3 Ligand 3 (Chitosan Derivative E), 14% N-acetyl-chitosan loaded with 0.6% of (S)—N-[4-[3-[3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[3-(2,5-dioxo- 2,5-dihydro-pyrrol-1-yl)-propionylamino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-1-oxopropyl]amino]ethoxy]-phenyl]-3-[2-[3-[guanidino]-benzoylamino]-acetylamino]-succinamic acid.

### Claim 15 (depends on 1)

A chitosan polymer derivative according to claim 1 which is:
Cs(NM)-Pr-S-αvβ3 Ligand 3 (Chitosan Derivative F), 14% N-acetyl-chitosan loaded with 1.9% of (S)—N-[4-[3-[3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[3-(2,5-dioxo- 2,5-dihydro-pyrrol-1-yl)-propionylamino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-1-oxopropyl]amino]ethoxy]-phenyl]-3-[2-[3-[guanidino]-benzoylamino]-acetylamino]-succinamic acid.

### Claim 16 (depends on 1)

A chitosan polymer derivative according to claim 1 which is:
Cs(NM)-Pr-S-αvβ3 Ligand 3 (Chitosan Derivative G), 14% N-acetyl-chitosan loaded with 6% of (S)—N-[4-[3-[3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[3-(2,5-dioxo-2,5-dihydro-pyrrol-1-yl)-propionylamino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-1-oxopropyl]amino]ethoxy]-phenyl]-3-[2-[3-[guanidino]-benzoylamino]-acetylamino]-succinamic acid.

### Claim 17 (depends on 1)

A chitosan polymer derivative according to claim 1 which is:
Cs(NM)-Pr-S-αvβ3 Ligand 3 (Chitosan Derivative H), 14% N-acetyl-chitosan loaded with 5.0% of (S)—N-[4-[3-[3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[3-(2,5-dioxo- 2,5-dihydro-pyrrol-1-yl)-propionylamino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-1-oxopropyl]amino]ethoxy]-phenyl]-3-[2-[3-[guanidino]-benzoylamino]-acetylamino]-succinamic acid.

### Claim 18 (depends on 1)

A chitosan polymer derivative according to claim 1 which is:
Cs(NM)-Pr-S-VLA4 Ligand 1 (Chitosan Derivative I), 14% N-acetyl-chitosan derivatized with 20% of (S)-3-[4-(2,6-dichlorobenzoylamino)phenyl]-2-[[[1-[2-[3-[2-[2-[2-[2-[2-[2-[2-[2-[3-(2,5-dioxo-2,5-dihydropyrrol-1-yl)propionylamino]-ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propionylamino]ethyl]cyclopentyl]carbonyl]amino]propionic acid.

### Claim 19 (depends on 1)

A chitosan polymer derivative according to claim 1 which is:
Cs(NM)-Pr-S-VLA4 Ligand 3 (Chitosan Derivative J), 14% N-acetyl-chitosan derivatized with 18% of (S)-2-[4-[(3-[2-[2-[2-[2-[2-[2-[2-[2-[3-(2,5-Dioxo-2,5-dihydropyrrol-1-yl)propionylamino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propionylamino)methyl]-2,6-difluorobenzoylamino]-3-[4-(1,3,6-trimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)phenyl]propionic acid.

### Claim 20 (depends on 1)

A chitosan polymer derivative according to claim 1 which is:
Cs(NM)-VLA4 Ligand 2 Acid (4% Loading) (Chitosan Derivative K), 14% N-acetyl-chitosan derivatized with 4% of N-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[1-(S)-1-carboxy-2-[4-(2,6-dichlorobenzoylamino)phenyl]ethylcarbamoyl]cyclopentyl]ethylcarbamoyl]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]succinamic acid.

### Claim 21 (depends on 1)

A pharmaceutical composition comprising: a compound according claim 1 and a pharmaceutically acceptable carrier.

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26 (depends on 2)

A pharmaceutical composition comprising a compound according to claim 2 and a pharmaceutically acceptable carrier.

### Claim 27 (depends on 3)

A pharmaceutical composition comprising a compound according to claim 3 and a pharmaceutically acceptable carrier.

### Claim 28 (depends on 4)

A pharmaceutical composition comprising a compound according to claim 4 and a pharmaceutically acceptable carrier.

### Claim 29 (depends on 5)

A pharmaceutical composition comprising a compound according to claim 5 and a pharmaceutically acceptable carrier.

### Claim 30 (depends on 6)

A pharmaceutical composition comprising a compound according to claim 6 and a pharmaceutically acceptable carrier.

### Claim 31 (depends on 7)

A pharmaceutical composition comprising a compound according to claim 7 and a pharmaceutically acceptable carrier.

### Claim 32 (depends on 8)

A pharmaceutical composition comprising a compound according to claim 8 and a pharmaceutically acceptable carrier.

### Claim 33 (depends on 9)

A pharmaceutical composition comprising a compound according to claim 9 and a pharmaceutically acceptable carrier.

### Claim 34 (depends on 10)

A pharmaceutical composition comprising a compound according to claim 10, wherein said compound is
Cs(AK)-Pr-S-αvβ3 Ligand 2 (Chitosan Derivative A), 2.5% N-acetyl-chitosan loaded with 0.15% of (S)—N-[4-[3-[3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[3-(2,5- dioxo-2,5-dihydro-pyrrol-1-yl)-propionylamino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-1-oxopropyl]amino]propoxy]-phenyl]-3-[2-[3-[guanidino]-benzoylamino]-acetylamino]-succinamic acid;
Cs(AK)-Pr-S-αvβ3 Ligand 2 (Chitosan Derivative B), 2.5% N-acetyl-chitosan loaded with 0.21% of (S)—N-[4-[3-[3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[3-(2,5- dioxo-2,5-dihydro-pyrrol-1-yl)-propionylamino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-1-oxopropyl]amino]propoxy]-phenyl]-3-[2-[3-[guanidino]-benzoylamino]-acetylamino]-succinamic acid;
Cs(AK)-Pr-S-αvβ3 Ligand 2 (Chitosan Derivative C), 2.5% N-acetyl-chitosan loaded with 0.76% of (S)—N-[4-[3-[3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[3-(2,5- dioxo-2,5-dihydro-pyrrol-1-yl)-propionylamino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxyl-1-oxopropyl]amino]propoxy]-phenyl]-3-[2-[3-[guanidino]-benzoylamino]-acetylamino]-succinamic acid.
Cs(NM)-Pr-S-αvβ3 Ligand 3 (Chitosan Derivative D), 14% N-acetyl-chitosan loaded with 0.3% of (S)—N-[4-[3-[3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[3-(2,5-dioxo- 2,5-dihydro-pyrrol-1-yl)-propionylamino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-1-oxopropyl]ainino]ethoxy]-phenyl]-3-[2-[3-[guanidino]-benzoylamino]-acetylamino]-succinamic acid;
Cs(NM)-Pr-S-αvβ3 Ligand 3 (Chitosan Derivative E), 14% N-acetyl-chitosan loaded with 0.6% of (S)—N-[4-[3-[3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[3-(2,5-dioxo- 2,5-dihydro-pyrrol-1-yl)-propionylamino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-1-oxopropyl]amino]ethoxy]-phenyl]-3-[2-[3-[guanidino]-benzoylamino]-acetylamino]-succinamic acid;
Cs(NM)-Pr-S-αvβ3 Ligand 3 (Chitosan Derivative F), 14% N-acetyl-chitosan loaded with 1.9% of (S)—N-[4-[3-[3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[3-(2,5-dioxo- 2,5-dihydro-pyrrol-1-yl)-propionylamino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-1-oxopropyl]amino]ethoxy]-phenyl]-3-[2-[3-[guanidino]-benzoylamino]-acetylamino]-succinamic acid;
Cs(NM)-Pr-S-αvβ3 Ligand 3 (Chitosan Derivative G), 14% N-acetyl-chitosan loaded with 6% of (S)—N-[4-[3-[3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[3-(2,5-dioxo-2,5-dihydro-pyrrol-1-yl)-propionylamino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-1-oxopropyl]amino]ethoxy]-phenyl]-3-[2-[3-[guanidino]-benzoylamino]-acetylamino]-succinamic acid;
Cs(NM)-Pr-S-αvβ3 Ligand 3 (Chitosan Derivative H), 14% N-acetyl-chitosan loaded with 5.0% of (S)—N-[4-[3-[3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[3-(2,5-dioxo- 2,5-dihydro-pyrrol-1-yl)-propionylamino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-1-oxopropyl]amino]ethoxy]-phenyl]-3-[2-[3-[guanidino]-benzoylamino]-acetylamino]-succinamic acid;
Cs(NM)-Pr-S-VLA4 Ligand 1 (Chitosan Derivative I), 14% N-acetyl-chitosan derivatized with 20% of (S)-3-[4-(2,6-dichlorobenzoylamino)phenyl]-2-[[[1-[2-[3-[2-[2-[2-[2-[2-[2-[2-[2-[3-(2,5-dioxo-2,5-dihydropyrrol-1-yl)propionylamino]-ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propionyl amino]ethyl]cyclopentyl]carbonyl]amino]propionic acid;
Cs(NM)-Pr-S-VLA4 Ligand 3 (Chitosan Derivative J), 14% N-acetyl-chitosan derivatized with 18% of (S)-2-[4-[(3-[2-[2-[2-[2-[2-[2-[2-[2-[3-(2,5-Dioxo-2,5-dihydropyrrol-1-yl)propionylamino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propionylamino)methyl]-2,6-difluorobenzoylamino]-3-[4-(1,3,6-trimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)phenyl]propionic acid; or
Cs(NM)-VLA4 Ligand 2 Acid (4% Loading) (Chitosan Derivative K), 14% N-acetyl-chitosan derivatized with 4% of N-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[1-(S)-1-carboxy-2-[4-(2,6-dichlorobenzoylamino)phenyl]ethylcarbamoyl]cyclopentyl]ethylcarbamoyl]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]succinamic acid.

### Claim 35 (depends on 1)

A method for the treatment of inflammation, cancer, or a metabolic disease or condition, said method comprising: administering to a patient in need thereof, a therapeutically effective amount of a compound according to claim 1.

### Claim 36 (depends on 2)

A method for the treatment of inflammation, cancer, or a metabolic disease or condition, said method comprising: administering to a patient in need thereof, a therapeutically effective amount of a compound according to claim 2.

### Claim 37 (depends on 3)

A method for the treatment of inflammation, cancer, or a metabolic disease or condition, said method comprising: administering to a patient in need thereof, a therapeutically effective amount of a compound according to claim 3.

### Claim 38 (depends on 4)

A method for the treatment of inflammation, cancer, or a metabolic disease or condition, said method comprising: administering to a patient in need thereof, a therapeutically effective amount of a compound according to claim 4.

### Claim 39 (depends on 5)

A method for the treatment of inflammation, cancer, or a metabolic disease or condition, said method comprising: administering to a patient in need thereof, a therapeutically effective amount of a compound according to claim 5.

### Claim 40 (depends on 6)

A method for the treatment of inflammation, cancer, or a metabolic disease or condition, said method comprising: administering to a patient in need thereof, a therapeutically effective amount of a compound according to claim 6.

### Claim 41 (depends on 7)

A method for the treatment of inflammation, cancer, or a metabolic disease or condition, said method comprising: administering to a patient in need thereof, a therapeutically effective amount of a compound according to claim 7.

### Claim 42 (depends on 8)

A method for the treatment of inflammation, cancer, or a metabolic disease or condition, said method comprising: administering to a patient in need thereof, a therapeutically effective amount of a compound according to claim 8.

### Claim 43 (depends on 9)

A method for the treatment of inflammation, cancer, or a metabolic disease or condition, said method comprising: administering to a patient in need thereof, a therapeutically effective amount of a compound according to claim 9.

### Claim 44 (depends on 34)

A method for the treatment of inflammation, cancer, or a metabolic disease or condition, said method comprising: administering to a patient in need thereof, a therapeutically effective amount of a compound according to claim 34.
